Dr. Lana McClements
Lecturer in Biotechnology | School of Life Sciences, Faculty of Science, University of Technology Sydney
Academic Women in Science (AWiS) Lead | Science Equity and Diversity, University of Technology Sydney
Committee Member | Health and Medical Research Ethics, University of Technology Sydney
Committee Member | Australian Society for Medical Research (ASMR), NSW, Australia
Honorary Positions | Southern University of Science and Technology, China; Queen’s University Belfast, UK
Associated Editor | Hypertension in Pregnancy
I am a qualified pharmacist with a MPharm degree from King's College London and five years experience as a clinical pharmacist in two biggest hospitals in London, providing both national and private healthcare. My research career started in 2010 when I enrolled into a PhD program at Queen's University Belfast. After 8 years at this wonderful university I moved to become an academic and women in science lead at the Faculty of Science at the University of Technology Sydney, one of the top 200 universities in the world.
As a principal investigator my main research focus is to develop better monitoring, risk stratification and treatment strategies for pregnant women with diabetes, and cardiovascular disease, later in life. We have patented a new blood biomarker of angiogenesis or vascular development, which can cause pre-eclampsia. This biomarker, FKBPL, can predict the risk of pre-eclampsia early in pregnancy as well indicate evolving preeclampsia therefore leading to early diagnosis. We continue to carry out cutting-edge research to understand this condition better, and have now further improved our prediction and diagnosis algorithm by adding another blood biomarker and clinical characteristics to it, and we have filed another patent. Pre-eclampsia is a dangerous pregnancy complication which can lead to significant morbidity and mortality in both mothers and babies. Women with diabetes have up to a four-fold increased incidence of developing this condition during pregnancy. Despite research efforts in this area, currently there are no reliable early biomarkers, effective preventative or treatment strategies for pre-eclampsia other than delivery. Our research programme focuses on developing novel early biomarkers and therapeutic strategies associated with aberrant angiogenesis, stem cell signalling, oxidative stress and metabolic dysfunction.